Prostate cancer affects an estimated 1 million men worldwide, with >300 000 dying from the disease each year.1 Prostate specific antigen (PSA) is a biomarker that is widely used to help detect prostate cancer before symptoms develop or at an early stage. This evidence concerns the gene KLK3 and Familial prostate cancer.